Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First half of 2025 (January 1, 2025 – June 30, 2025)
Filing Date: August 6, 2025
Novo Nordisk reported strong top-line growth driven by its Obesity care portfolio, particularly Wegovy, and GLP-1 diabetes treatments. However, the company lowered its full-year 2025 outlook due to persistent competition from compounded GLP-1s in the US and slower-than-expected market expansion. Significant corporate governance changes were announced, including the appointment of Maziar Mike Doustdar as the new President and CEO, effective August 7, 2025.
Key Financial Metrics (H1 2025)
| Metric | H1 2025 (DKK million) | H1 2024 (DKK million) | Growth (Reported) | Growth (Constant Exchange Rates) |
|---|---|---|---|---|
| Net Sales | 154,944 | 133,409 | 16% | 18% |
| Operating Profit | 72,240 | 57,780 | 25% | 29% |
| Net Profit | 55,537 | 45,457 | 22% | N/A |
| Diluted EPS | 12.49 DKK | 10.17 DKK | 23% | N/A |
| Free Cash Flow | 33,571 | 41,309 | (19%) | N/A |
| Capital Expenditure (PP&E) | 28,083 | 18,944 | 48% | N/A |
| Operating Margin | 46.6% | 43.3% | +330 bps | N/A |
Debt and Liquidity: Total borrowings stood at DKK 99.3 billion (DKK 87.3 billion non-current + DKK 11.96 billion current) as of June 30, 2025. Cash and cash equivalents were DKK 18.4 billion. The company issued EUR 6 billion in Eurobonds in May 2025.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 16% (18% at CER). Obesity care sales surged 56% (58% at CER) to DKK 38.8 billion, driven by Wegovy. Diabetes care sales grew 6% (8% at CER).
- Profitability: Operating profit grew 25% (29% at CER). This growth was aided by a DKK 5.7 billion impairment loss on ocedurenone in H1 2024, which is not present in the current period.
- Cost Structure: R&D costs decreased 11% year-over-year, primarily due to the absence of the prior year's impairment loss. Sales and distribution costs rose 15% due to promotional activities for Wegovy and Ozempic.
- US Operations: Sales were positively impacted by gross-to-net adjustments related to prior years, including a DKK 3 billion adjustment for the 340B provision in Q2 2025.
- Market Share: Global diabetes value market share declined 1.4 percentage points to 32.6% (MAT), while the company maintains a 64.6% branded volume market share in the global obesity market.
Guidance, Outlook, and Risks
Updated 2025 Outlook
Novo Nordisk has lowered its full-year 2025 guidance:
- Sales Growth: Now expected to be 8-14% at CER (previously 13-21%).
- Operating Profit Growth: Now expected to be 10-16% at CER (previously 16-24%).
- Free Cash Flow: Now expected to be DKK 35-45 billion (previously DKK 56-66 billion).
Drivers for Lowered Outlook: The reduction is attributed to lower growth expectations for the second half of 2025, specifically for Wegovy in the US obesity market and Ozempic in the US GLP-1 diabetes market. Key headwinds include the persistent use of compounded GLP-1s, slower market expansion, and competition.
Management Commentary and Risks
- Compounded GLP-1s: Management highlighted that unsafe and unlawful mass compounding continues in the US despite the FDA grace period expiring in May 2025, impacting Wegovy uptake in the cash channel.
- Supply Constraints: Periodic supply constraints and drug shortage notifications continue to affect certain products and geographies.
- Leadership Transition: Lars Fruergaard Jørgensen is stepping down as CEO after 34 years. Mike Doustdar succeeds him on August 7, 2025. Martin Holst Lange will lead the consolidated R&D unit.
- Regulatory: The company expects a regulatory decision on the Wegovy MASH indication in Q3 2025. Ozempic received a positive CHMP opinion for peripheral arterial disease.
Investor Verification Checklist
- Compounded GLP-1 Impact: Verify the extent to which compounded semaglutide is eroding Wegovy market share in the US cash channel versus the insured channel.
- 340B Provision: Confirm the stability of the DKK 3 billion gross-to-net adjustment in Q2 2025 and the remaining provision of USD 4.2 billion for 340B statutory discounts.
- Supply Chain Capacity: Assess the timeline for the new manufacturing capacity (Catalent sites and other expansions) to meet demand, given the reported periodic supply constraints.
- Leadership Execution: Monitor the strategic execution under the new CEO, Mike Doustdar, particularly regarding commercial efficiency and cost base optimization.
- Regulatory Approvals: Track the Q3 2025 decision on the Wegovy MASH indication and the potential impact on reimbursement and market access.